Significant progress has been made in understanding the molecular genetic alterations
involved in sarcomagenesis. Cytogenetic and molecular studies have identified nonrandom …

Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …

Antiphospholipid syndrome (APS) is defined by recurrent pregnancy loss and thrombosis in
the presence of antiphospholipid (aPL) Ab’s. Currently, therapy for pregnant women with …

Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). …

The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine
kinase BRAF and causes excessive activity in the mitogen-activated protein kinase …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, …

High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability 1
, 2 , 3 – 4 patterned by distinct mutational processes 5 , 6 , tumour heterogeneity 7 , 8 – 9 …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors
evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of …

Chromosomal instability promotes metastasis by generating chronic tumor inflammation.
ENPP1 facilitates metastasis and enables tumor cells to tolerate inflammation by hydrolyzing …